News

Laurent Pharmaceuticals Receives Health Canada’s Approval to Initiate Phase 2/3 Clinical Trial in Long COVID

29 August 2023

The ESSOR study is a natural extension to our ongoing evaluation of LAU-7b as a next-generation COVID-19 therapeutic, which generated positive...

Read More

LAU-7b featured in The Pharmaceutical Journal among next-generation antivirals targeting COVID-19

19 January 2023

LAU-7b featured in The Pharmaceutical Journal (The Royal Pharmaceutical Society) among next-generation antivirals targeting COVID-19

Read More

EVENTS

Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference, May 17-22, San Diego, CA, USA
read more
Laurent Pharma to participate to BIO International Convention,  June 3-6 2024, San Diego, CA, USA
read more

Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA

read more
Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
read more
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022
read more